Nachrichten zur Swedish Orphan Biovitrum AB Aktie

Additional Analyses From Phase 3 study With Doptelet ® (avatrombopag) for the treatment of Chronic Immune Thrombocytopenia Provides Evidence of Long-term Response Rates

STOCKHOLM , Dec. 9, 2019 /PRNewswire/ -- Dova Pharmaceuticals, a wholly owned subsidiary of…

Sobi Successfully Completes Acquisition of Dova Pharmaceuticals

STOCKHOLM , Nov. 12, 2019 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) (STO:…

Sobi Successfully Completes Tender Offer for All Outstanding Shares of Dova Pharmaceuticals

STOCKHOLM , Nov. 10, 2019 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) (STO:…

Swedish Orphan Biovitrum AB (publ) (BIOVF) CEO Guido Oelkers on Q3 2019 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Swedish Orphan Biovitrum AB (publ) 2019 Q3 - Results - Earnings Call Presentation

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Swedish Orphan Biovitrum AB reports Q3 results

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Dova Pharmaceuticals rallies on buyout offer from Swedish Orphan Biovitrum

Dova Pharmaceuticals shares climbed 37% to $27.75 a share in premarket trade after Swedish Orphan Biovitrum said it…

Dova Pharmaceuticals to Be Bought by Swedish Orphan Biovitrum for $915M

Um den gesamten Artikel unter thestreet.com zu lesen, klicken Sie bitte auf die Überschrift...…

Endo Gains FDA Nod for Orfadin Generic to Treat Rare Disease

Endo (ENDP) receives an FDA approval for the generic equivalent of Swedish Orphan Biovitrums Orfadin....…

Sobi has Entered Into Agreement to Sell Priority Review Voucher

STOCKHOLM , Aug. 22, 2019 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ)…

Swedish Orphan Biovitrum AB (publ) (BIOVF) CEO Guido Oelkers on Q2 2019 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Swedish Orphan Biovitrum AB (publ) 2019 Q2 - Results - Earnings Call Slides

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Sobi Publishes Report for Second Quarter 2019

STOCKHOLM , July 17, 2019 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ)…

People With Haemophilia and Female Carriers in Sweden Have Higher Risk of Anxiety, Depression and Pain, Based on Treatment Patterns: Swedish Orphan Biovitrum

STOCKHOLM , July 8, 2019 /PRNewswire/ -- People with haemophilia have an increased risk…

New Data Demonstrates Impact of Emapalumab in Patients With Macrophage Activation Syndrome (MAS)

STOCKHOLM , June 18, 2019 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ)…

Rare Strength Powers Growth - Sobi Capital Markets Day 2019

STOCKHOLM , May 14, 2019 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ)…

Swedish Orphan Biovitrum AB (BIOVF) CEO Guido Oelkers on Q1 2019 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Swedish Orphan Biovitrum AB (publ) 2019 Q1 - Results - Earnings Call Slides

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Sobi Publishes 2018 Annual and Sustainability Report

STOCKHOLM , April 18, 2019 /PRNewswire/ - Swedish Orphan Biovitrum AB (publ)…

Invitation to Sobi Capital Markets Day 14 May 2019

STOCKHOLM , Feb. 21, 2019 /PRNewswire/ -- Save the date for Swedish…

Swedish Orphan Biovitrum AB 2018 Q4 - Results - Earnings Call Slides

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

AstraZeneca completes sale of respiratory tract treatment to Sobi for $1.6bn

AstraZeneca said it had completed an agreement to sell the US rights to lower respiratory tract infection treatment Synagis to…

Sobi Completes Acquisition of Synagis® US Rights From AstraZeneca and Exercises Authorisation to Issue Shares

STOCKHOLM , Jan. 24, 2018 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ)…

FDA Approves Gamifant® (emapalumab), the First and Only Treatment for Primary Haemophagocytic Lymphohistiocytosis (HLH)

STOCKHOLM , Nov 20, 2018 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ)…

Swedish Orphan Biovitrum Acquires Synagis U.S. Rights

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Swedish Orphan Biovitrum ABs (BIOVF) CEO Guido Oelkers on Merger & Acquisition Conference - Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Astrazeneca verkauft US-Rechte an Synagis für 1,5 Mrd US-Dollar

Von Carlo Martuscelli FRANKFURT (Dow Jones)--Der Pharmakonzern Astrazeneca verkauft die US-Rechte am Mittel Synagis an die Swedish Orphan Biovitrum (Sobi)…

AstraZeneca sells infant drug rights to Sobi for $1.5 bln upfront

AstraZeneca took another step to refocus its portfolio on priority projects on Tuesday by selling U.S. rights to a treatment for a…

AstraZeneca sells US rights to respiratory tract infection treatment

AstraZeneca said Tuesday it had agreed to sell the US rights to its respiratory tract infection treatment to Swedish Orphan…

Sobi to Acquire Synagis® US Rights From AstraZeneca - Creates a Platform for Global Growth

STOCKHOLM , Nov. 13, 2018 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ)…

Swedish Orphan Biovitrum AB (BIOVF) CEO Guido Oelkers on Q3 2018 Results - Earnings Call Transcript

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Swedish Orphan Biovitrum AB 2018 Q3 - Results - Earnings Call Slides

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Sobi Completes Acquisition of the Global Rights for Emapalumab From Novimmune

STOCKHOLM , August 23, 2018 /PRNewswire/ -- Following approvals from relevant competition authorities, …

First Patient Dosed in Phase 1/2 Study Evaluating SOBI003 for Treatment of Mucopolysaccharidosis Type IIIA (MPS IIIA)

STOCKHOLM , Aug.10, 2018 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) announces that…

Swedish Orphan Biovitrum AB ADR 2018 Q2 - Results - Earnings Call Slides

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Gene Therapy for Mucopolysaccharidosis Pipeline Analysis Report 2018 Featuring Sangamo Therapeutics, Swedish Orphan Biovitrum & uniQure

DUBLIN, June 15, 2018 /PRNewswire/ -- The "Gene Therapy for Mucopolysaccharidosis - A Pipeline Analysis Report" report…

Swedish Orphan Biovitrum AB ADR 2017 Q4 - Results - Earnings Call Slides

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Kineret® (anakinra) Receives a Positive Opinion from CHMP for the Treatment of Stills Disease

STOCKHOLM, Feb. 23, 2018 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) today announces that the Committee for Medicinal Products…

Sobis metabolic disorder drug secures fast track status in US

The US Food and Drug Administration (FDA) has accepted Swedish Orphan Biovitrums (Sobi) new drug application and granted fast track…

FDA Accepts Investigational New Drug Application and Grants Fast Track Status for SOBI003 for the Treatment of MPS IIIA

STOCKHOLM, Jan. 23, 2018 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) announces that the FDA has…

Sobi - First Patient Randomised in a Phase 3 Study Evaluating Safety and Efficacy of Anakinra in the Treatment of Stills Disease

STOCKHOLM, Nov. 16, 2017 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) announces that the first patient…